Financials
Financial year 2025
ENESTIA BELGIUM from Hamont-Achel, company number BE0401304737, closed financial year 2025 with a result of € 9.9 million after tax. For that financial year ENESTIA BELGIUM recorded revenue of € 48.1 million and equity of € 25.7 million. Compared with financial year 2024, the result moved from € 5.7 million to € 9.9 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 10, 2026.
€ 25.7 million
▲ 21% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 9.9 million
▲ 73% vs 2024
Profit after tax over the fiscal year.
€ 776,788
▲ 212% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 5.5 million paid out
56 % of the profit went to the shareholders, mostly to Sharp Clinical Holdings Europe limited (100 % of the shares). That is where the money ends up.
People and assets in 2025
210.2
▲ 8.4 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 14.9 million
▲ 9% vs 2024
€ 71,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 332,944
▲ 26% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 4.4 million
▲ 29% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 80 days on average.
€ 2.5 million
▲ 6% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 27,095,973 | € 32,380,520 | € 38,437,704 | € 48,146,326 | ▲ 25% |
| Profit after taxes | € 2,399,509 | € 3,170,173 | € 5,706,227 | € 9,884,024 | ▲ 73% |
| Equity | € 16,962,447 | € 20,132,619 | € 21,338,846 | € 25,722,871 | ▲ 21% |
| Total debts | € 14,749,711 | € 24,574,277 | € 29,350,735 | € 38,562,585 | ▲ 31% |
| Cash | € 6,133,525 | € 8,205,471 | € 249,212 | € 776,788 | ▲ 212% |
| Land & buildings | € 3,769,116 | € 3,307,548 | € 3,330,738 | € 7,463,329 | ▲ 124% |
| Retained profit | € 1,833,852 | € 5,004,024 | € 6,210,251 | € 10,594,275 | ▲ 71% |
| Dividend | € 0 | € 0 | € 4,500,000 | € 5,500,000 | ▲ 22% |
| Balance sheet total | € 31,819,556 | € 44,753,978 | € 50,725,584 | € 64,310,379 | ▲ 27% |
| Employees (FTE) | 201.9 | 202.7 | 201.8 | 210.2 | ▲ 8.4 |
Key figures of ENESTIA BELGIUM, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to ENESTIA BELGIUM?
What happened at ENESTIA BELGIUM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Robert O'Beirn stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 9.9 million (▲ 73% vs 2024). Source: NBB ↗
- Paul Flaherty stepped down as director. NBB
- Guido Martens stepped down as director. NBB
- Paul Flaherty became a director. NBB
- Guido Martens became a director. NBB
- Robert O'Beirn became a director. NBB
- New establishment in Hamont-Achel. KBO
In short
From € 2.4 million profit in 2022 to € 9.9 million profit in 2025.
Paid € 5.4 million in corporate taxes since 2022.
Best year ever: 2025, with € 9.9 million profit.
Paid out € 10 million in dividends to the owners in total.
A new publication or filing at ENESTIA BELGIUM? We notify you, reason included.
Follow ENESTIA BELGIUMDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by Sharp Clinical Holdings Europe limited (100%).
Directors
According to the 2025 annual accounts
Paul Flaherty
Director
since 2020 · until 2026
Guido Martens
Director
since 2020 · until 2026
Robert O'Beirn
Director
since 2019 · until 2031
Shareholders
Sharp Clinical Holdings Europe limited
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Klöcknerstraat 1
3930 Hamont-Achel
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0401.304.737
- VAT number
- BE 0401.304.737
- Registered office
- Klöcknerstraat 1, 3930 Hamont-Achel
- Names & denominations
- ENESTIA BELGIUM
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 5 November 1959
- Peppol
- Active · Active since 6 Nov 2025
- Activities · NACE
Activiteiten van verpakkingsbedrijven
Verpakkingsbedrijven